secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001171843-25-000155
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst reports FY2024 ORLADEYO net revenue $437M (+34% YoY), guides FY2025 $515-535M
--------------------------------------------------------------------------------

- Preliminary FY2024 ORLADEYO net revenue $437M (+34% YoY); Q4 net revenue $123.5M (+36% YoY).
- Total FY2024 revenue $450M (+36% YoY); FY2025 total revenue guidance $540-560M.
- Expects to approach quarterly EPS profitability and positive cash flow in 2H 2025; targets full-year EPS profitability and positive cash flow in 2026.
- Plans 2025 NDA for ORLADEYO granules for children <12; two new pipeline programs to enter clinic (BCX17725, avoralstat).
- 2025 GAAP op ex guidance $485-495M (incl. ~$60M stock comp); non-GAAP op ex $425-435M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325000155/0001171843-25-000155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325000155/f8k_011025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer